253 related articles for article (PubMed ID: 2190661)
1. Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia.
Urban C; Schwinger W; Slavc I; Schmid C; Gamillscheg A; Lackner H; Hauer C; Pakisch B
Bone Marrow Transplant; 1990 May; 5(5):353-6. PubMed ID: 2190661
[TBL] [Abstract][Full Text] [Related]
2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
3. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
4. Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect?
Rassam SM; Katz F; Chessells JM; Morgan G
Bone Marrow Transplant; 1993 Mar; 11(3):247-50. PubMed ID: 8467291
[TBL] [Abstract][Full Text] [Related]
5. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
6. Relapse of chronic myeloid leukemia (CML) in lymphoid crisis after allogeneic bone marrow transplantation for CML in chronic phase with busulfan plus cyclophosphamide regimen.
Takami A; Chuhjo T; Nakao S
Haematologica; 2002 Jun; 87(6):659-61. PubMed ID: 12031925
[No Abstract] [Full Text] [Related]
7. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
[TBL] [Abstract][Full Text] [Related]
8. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kröger N; Krüger W; Wacker-Backhaus G; Hegewisch-Becker S; Stockschläder M; Fuchs N; Rüssmann B; Renges H; Dürken M; Bielack S; de Wit M; Schuch G; Bartels H; Braumann D; Kuse R; Kabisch H; Erttmann R; Zander AR
Bone Marrow Transplant; 1998 Dec; 22(11):1029-33. PubMed ID: 9877263
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
Muñoz A; Bureo E; Ortega JJ; Richard C; Olivé T; Maldonado MS; Madero L; Díaz MA
Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
[TBL] [Abstract][Full Text] [Related]
10. [Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
Glejzer O; Sedzimirska M; Tomaszewska-Toporska B; Tomeczko J; Kołodziej J; Pacuszko T; Was A; Bocheńska J; Jaźwiec B; Klimczak A
Acta Haematol Pol; 1992; 23(2 Suppl 1):49-59. PubMed ID: 1488872
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
[TBL] [Abstract][Full Text] [Related]
12. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
[TBL] [Abstract][Full Text] [Related]
13. [Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
Matsue K; Tohi T; Masauji N; Tsukuda K
Rinsho Ketsueki; 1992 Mar; 33(3):338-42. PubMed ID: 1578638
[TBL] [Abstract][Full Text] [Related]
14. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide.
Avalos BR; Klein JL; Kapoor N; Copelan EA
Bone Marrow Transplant; 1993 Dec; 12(6):655-8. PubMed ID: 8136749
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects.
Thall PF; Champlin RE; Andersson BS
Bone Marrow Transplant; 2004 Jun; 33(12):1191-9. PubMed ID: 15122310
[TBL] [Abstract][Full Text] [Related]
18. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
Saikia TK; Advani SH; Parikh PM; Bapna A; Somjee S; Mukhopadhyay A; Gopal R; Nair CN
J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
Kalaycioglu ME; Bolwell BJ
Bone Marrow Transplant; 1994 Jul; 14(1):113-5. PubMed ID: 7951097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]